spacer
The Healthcare Sales & Marketing Network celebrates 21 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  HPV Vaccine 

 HSMN NewsFeed - 28 Mar 2017
Antiva Biosciences Closes $22 Million Series C Financing
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 1 Oct 2015
Synthetic Biologics Appoints Raymond Stapleton, PhD, as Senior Vice President, Manufacturing
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 Aug 2015
Inovio Pharmaceuticals Enters Into Strategic Cancer Vaccine Collaboration and License Agreement With MedImmune
Biopharmaceuticals Licensing
 HSMN NewsFeed - 9 Oct 2012
Vaxxas Appoints David Hoey as Company’s First CEO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Dec 2010
US FDA Approves New Indication for Merck's HPV Vaccine, GARDASIL(R)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 25 Feb 2010
Barry Buckland Joins Ancora Pharmaceuticals Board
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Feb 2010
In Phase III Data Merck's GARDASIL(R) Was Efficacious Against Anal Disease Caused by HPV-6,11,16 and 18
Biopharmaceuticals
 HSMN NewsFeed - 13 Nov 2008
GARDASIL®, Merck's Cervical Cancer Vaccine, Demonstrated Efficacy in Preventing HPV-Related Disease in Males in Phase III Study
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 May 2008
Study Finds QIAGEN's HPV Test Offers Greater Long-term Protection from Cervical Disease than the Pap
Diagnostics
 HSMN NewsFeed - 14 May 2008
CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date
Biopharmaceuticals
 HSMN NewsFeed - 10 Mar 2008
GSK Cervical Cancer Candidate Vaccine CERVARIX (R) Demonstrates Long-Term Protection for More Than Six Years
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Nov 2007
High-price Vaccines Spark Four-fold Growth in Pediatric & Adolescent Vaccines Market
Biopharmaceuticals
 HSMN NewsFeed - 4 Nov 2007
New Data Presented on GARDASIL(R), Merck's Cervical Cancer Vaccine, in Women Through Age 45
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Jun 2007
Bio-Bridge Science Issues Corporate Update
Biopharmaceuticals
 HSMN NewsFeed - 9 May 2007
New England Journal of Medicine Publishes New Data on GARDASIL(R), Merck's Cervical Cancer Vaccine
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Apr 2007
Astrazeneca to Acquire Medimmune for $58 Per Share in a Fully Recommended, All-Cash Transaction with a Total Enterprise Value of $15.2 Billion
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 22 Mar 2007
CDC Finalizes Advisory Panel Recommendations for GARDASIL(R), Merck's Cervical Cancer Vaccine
Biopharmaceuticals
 HSMN NewsFeed - 18 Jan 2007
GlaxoSmithKline Initiates Head-to-Head Study of Cervical Cancer Vaccines
Biopharmaceuticals
 HSMN NewsFeed - 7 Nov 2006
Cleveland Clinic Unveils 'Top 10' Medical Innovations for 2007
Devices Biopharmaceuticals Cardiology Oncology Neurology
 HSMN NewsFeed - 30 Oct 2006
Mathematical Model Based on Clinical Findings From Cervarix(TM), GSK's Cervical Cancer Candidate Vaccine, Suggests Vaccination Could Reduce Cervical Cancers by up to 80%
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Sep 2006
Mathematical Model Predicts That CERVARIX May Prevent Nearly 80 Percent of Cervical Cancers
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Sep 2006
Carrington Subsidiary to Develop Needle-less Delivery of Cervical Cancer Vaccine With the National Cancer Institute (NCI)
Biopharmaceuticals Drug Delivery Oncology
 HSMN NewsFeed - 22 Sep 2006
European Commission Approves GARDASIL(R), Merck's Cervical Cancer Vaccine
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 12 Jul 2006
Latest Data Confirm GlaxoSmithKline's Proprietary Adjuvant System For Cervarix(TM) Induces a Stronger and More Sustained Immune Response Than a Conventional Adjuvant Formulation
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Jun 2006
GlaxoSmithKline Applauds ACIP for New Guidance on Use of HPV Vaccine to Protect Girls and Women Against Cervical Cancer
Biopharmaceuticals
 HSMN NewsFeed - 5 Apr 2006
Cervarix(TM), GSK's Candidate Vaccine for Cervical Cancer, Demonstrated Sustained Efficacy for up to 4.5 Years and Broader Protection Against Cancer- Causing HPV Types
Biopharmaceuticals
 HSMN NewsFeed - 27 Feb 2006
AVANT Announces that the European Regulatory Authorities Have Approved Rotarix(R) Rotavirus Vaccine
Biopharmaceuticals Regulatory
Return to NewsFeed  

 Additional items found! 6

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 6 additional stories matching:
HPV Vaccine
(Password required)
FindReps 2 - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps 2 - available on the Apple App Store for iPhone and iPad.